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Abstract 24 
Pattern recognition receptors, including the Toll-like receptors (TLRs), are important in the induction 25 
and activation of two critical arms of the host defence to pathogens and microorganisms; the rapid 26 
innate immune response (as characterised by the production of Th1 promoting cytokines and type 1 27 
interferons) and the adaptive immune response. Through this activation, ligands and agonists of TLRs 28 
can enhance immunotherapeutic efficacy. Resiquimod is a small (water-soluble) agonist of the 29 
endosome-located Toll-like receptors 7 and 8 (TLR7/8). However due to its molecular attributes it 30 
rapidly distributes throughout the body after injection. To circumvent this, these TLR agonists can be 31 
incorporated within delivery systems, such as liposomes, to promote the co-delivery of both antigen 32 
and agonists to antigen presenting cells. In this present study, resiquimod has been chemically 33 
conjugated to a lipid to form a lipid-TLR7/8 agonist conjugate which can be incorporated within 34 
immunogenic cationic liposomes composed of dimethyldioctadecylammonium bromide (DDA) and 35 
the immunostimulatory glycolipid trehalose 6,6’ – dibehenate (DDA:TDB). This DDA:TDB-TLR7/8 36 
formulation offers similar vesicle characteristics to DDA:TDB (size and charge) and offers high 37 
retention of both resiquimod and the electrostatically adsorbed TB subunit antigen Ag85B-ESAT6-38 
Rv2660c (H56). Following immunisation through the intramuscular (i.m.) route, these cationic 39 
liposomes form a vaccine depot at the injection site. However, immunisation studies have shown that 40 
this biodistribution does not translates into notably increased antibody nor Th1 responses at the 41 
spleen and draining popliteal lymph node. This work demonstrates that the conjugation of TLR7/8 42 
agonists to cationic liposomes can promote co-delivery but the immune responses stimulated do not 43 
merit the added complexity considerations of the formulation. 44 
45 
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Introduction 46 
Cationic liposomes composed of dimethyldioctadecylammonium bromide (DDA) and the 47 
immunostimulatory glycolipid trehalose 6,6’ – dibehenate (otherwise known as DDA:TDB or CAF01) 48 
have been shown to be an potent adjuvant and produce a Th1-biased immune response, when in 49 
combination with a range of sub-unit vaccines including chlamydia, influenza, HIV and tuberculosis 50 
vaccine (e.g. [1-5]).  The adjuvanticity of DDA:TDB is in part ascribed to surface charge; the cationic 51 
nature of these liposomes allow them to adsorb anionic antigens and thereby mediate co-delivery of 52 
antigen and adjuvant to antigen presenting cells (APCs). DDA:TDB liposomes have also been shown to 53 
promote the formation of an antigen/adjuvant ‘depot’ at the injection site, followed by a sustained 54 
release to the draining lymph nodes [5, 6]. By following the fate of radio-labelled liposomes and 55 
antigen, biodistribution studies have demonstrated that the cationic charge (resulting from the 56 
quaternary ammonium present in the structure of the surfactant DDA), the high antigen adsorption, 57 
and the membrane rigidity of the DDA:TDB liposomes at body temperature (Tm ~ 42°C) promote the 58 
formation of this depot [5, 6]. By this means, APCs are recruited to the site of injection where they 59 
engulf the liposomal-antigen system. Subsequently, these immune cells become activated and move 60 
to the draining lymph nodes where they present the antigen to T cells and activating them [6].  The 61 
presence of TDB within the formulation also plays an important role promoting enhanced activation 62 
of APCs through interaction with the C-Lectin type receptor (CLR) Mincle [7, 8].  63 
To further potentiate liposomal adjuvants, immunostimulatory agonists of Toll-like receptors can be 64 
included within the formulation. For example, CD8+ immunopotentiators, such as 65 
polyinosinic:polycytidylic acid (polyI:C) (TLR3) and unmethylated CpG oligodeoxynucleotides (CpG 66 
ODN) (TLR9) have be formulated within the liposome vaccine adjuvants in order to enhance their 67 
ability to promote immune responses [9-11]. Small molecule agonists, such as the TLR7/8 agonist 68 
resiquimod, can also be considered. However, their efficacy to act as a vaccine adjuvant can be 69 
variable; due to their molecular attributes, upon injection they are rapidly distributed throughout the 70 
body. This limits the ability of small molecule agonists to promote local activation of dendritic cells 71 
and hence activation of the immune response [12]. Therefore formulating these agonists to remain at 72 
the injection site may be important for optimal adjuvant activity, through either topical or dermal 73 
application [13-15], as well as incorporation within liposomes [16, 17]. Resiquimod is a synthetic 74 
imidazoquinoline compound with potent activity as an anticancer and antiviral agent as well as a 75 
vaccine adjuvant [12, 18, 19]. Several studies evaluating the incorporation of resiquimod as a vaccine 76 
adjuvant have been carried out with a wide range of antigens and animal species. In general, TLR7/8 77 
agonists increase the production of Th1 cytokines (such as IFN-ɣ, IL-2 and TNF-α) whereas the 78 
production of Th2 cytokines (such as IL-5) is inhibited [20-22]. Unfortunately, studies have shown 79 
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limited effectiveness of TLR7/8 agonists when compared to other TLR agonists [23, 24]. This might be 80 
due to their small size (e.g. resiquimod ~ 500 Da) and therefore, their fast distribution from the 81 
application site which results in reduced co-delivery and decreased adjuvant effect [25]. Another 82 
disadvantage is the systemic side effects observed after administration of small size TLR7/8 agonists 83 
[26]. In order to prolong the retention time of these TLR7/8 agonists at the site of application and 84 
reduce these side effects, different approaches through formulation design and delivery have been 85 
evaluated. This includes encapsulation in liposomes [27], topical application of antigen and resiquimod 86 
[28-30], conjugation of TLR7/8 agonists to antigens [31], polymers [32] or polysaccharides [33], 87 
modification of the molecular structure of the agonist itself [16, 34], and combination of TLR7/8 88 
agonists with other adjuvants [35]. However, despite these studies, vaccine responses have been 89 
variable and the adjuvant efficacy of these systems has yet to be fully exploited. 90 
Therefore the aim of this study was to consider if the adjuvant action of the cationic DDA:TDB 91 
liposomal adjuvants could be further potentiated by conjugating a TLR7/8 agonist to the liposome 92 
construct. To achieve this, we chemically synthesised a lipid-TLR7/8 agonist constructed from the 93 
phospholipid 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) and resiquimod. This 94 
conjugate can be incorporated into the CAF01 liposome system such that the TLR agonist can be 95 
displayed on the liposome surface alongside the H56 tuberculosis antigen (Ag85B-ESAT-6-Rv2660c) to 96 
potentially enhance vaccine adjuvant activity. 97 
 98 
Methods 99 
Materials 100 
Dimethyldioctadecylammonium bromide (DDA), 1,2 - distearoyl-sn-glycero-3-phosphoethanolamine 101 
(DSPE) and the immunostimatory glycolipid trehalose 6,6′-dibehenate (TDB) were purchased from 102 
Avanti Polar Lipids, Inc. (Alabaster, AL, USA). The Toll-Like Receptor (TLR) agonist, resiquimod was 103 
purchased from Sigma Aldrich (St. Louis, MO). Hydrogen peroxide, succinic anhydride, 104 
triphenylphosphine, sephadex™ G-75, sodium hydroxide, sodium thiosulphate, magnesium sulphate, 105 
hydrogen peroxide, sodium chloride, concanavalinA (ConA), diisopropyl azodicarboxylate (DIAD), 106 
heparin, sodium hydroxide, crystal sky blue (Pontamine blue), phospho-buffered saline (PBS) tablets, 107 
2,2 –azino-bis (3-ethylenebenzthiazoline-6-sulfonic acid (ABTS), citric acid, protease inhibition 108 
mixture, sodium azide, HEPES buffer and Triton-X 100 were purchased from Sigma Aldrich (St. Louis, 109 
MO). Foetal Bovine serum (FBS) and RPMI 1640 cell culture medium (without L-glutamine) were from 110 
Biosera, UK. Penicillin-streptomycin-glutamine (PSG; 100 x liquid) was from Invitrogen. For 111 
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radiolabelling, tritium-labelled cholesterol (3H-Chol) was obtained from GE Healthcare (Amersham, 112 
UK), IODOGEN® pre-coated iodination tubes from Pierce Biotechnology (Rockford, IL) and 125I (NaI in 113 
NaOH solution), SOLVABLE™ and UltimaGold™ scintillation fluid were purchased from Perkin Elmer 114 
(Waltham, MA). Ag85B-ESAT6-Rv2660c (H56 TB subunit vaccine antigen) was provided by Statens 115 
Serum Institut, Denmark at a concentration of 1.6 mg/mL. Methanol, ethyl acetate, and chloroform 116 
(all HPLC grade) were purchased from Fisher Scientific (Leicestershire, UK). Tris-base, obtained from 117 
IDN Biomedical, Inc (Aurora, Ohio) was used to make Tris buffer and adjusted to pH 7.4, unless 118 
otherwise stated. Trehalose [D-Trehalose (99 %) anhydrous] was obtained from Acros Organics. 119 
Duoset Sandwich ELISA kits and solutions (IFN-γ, IL-17, IL-2, IL-5, IL-6, IL-10, IL-1β, IL-18 and IL-33) were 120 
obtained from R & D Systems. Deuteriated chloroform and dimethylsulfoxide (DMSO) were both 121 
purchased from Cambridge Isotope Laboratories (MA, USA). Silica gel 60 and TLC Silica 60 plates were 122 
purchased from Merck (Darmstadt, Germany). All antibody-specific immunoglobulins (IgG, IgG1 and 123 
IgG2b) were purchased from AbD SeroTec. Double distilled water was used to make buffers and 124 
solutions used. 125 
 126 
Chemical Synthesis 127 
Step 1 formation of the succinyl - linker: DSPE lipid and succinic anhydride (SA) were dissolved in 128 
chloroform/methanol (9:1 v/v) at a ratio of 1:5 M/M and the reaction was completed at room 129 
temperature overnight (Figure 1). The progress of the succinylation reaction [36] was monitored by 130 
TLC and gave a complete conversion. For work up the mixture was ‘quenched’ by the addition of 131 
sodium hydroxide (NaOH) at a 1M concentration. The organic phase was dried with magnesium 132 
sulphate (MgSO4) and the succinyl – DSPE linker was obtained in quantitative yield as solid 133 
intermediate.  134 
Step 2 Conjugation of resiquimod by Mitsunobu reaction: The succinyl – DSPE linker and resiquimod 135 
were added together during this reaction at a 1:1 M/M ratio for complete reaction. A solution of DIAD, 136 
diisopropyl-azodicarboxylate in THF (1 M) was added to the mixture under Nitrogen gas atmosphere 137 
followed by 1.0 eq. of solid TPP, triphenylphosphine. The reaction was performed at room 138 
temperature over 2 hours, under magnetic stirring and controlled by TLC. Upon completion of the 139 
reaction as described previously excess water was ‘quenched’ by the addition of sodium hydroxide 140 
(NaOH) at a 1M concentration. The crude conjugated adduct was purified by column chromatography 141 
with ethyl acetate using silica gel. The DSPE -resiquimod conjugate was fully analysed by MS, IR and 142 
NMR spectroscopy to confirm the product. 143 
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Preparation of liposomes  144 
Liposome formulations were prepared by the previously established lipid film hydration method [37]. 145 
Stock lipid solutions were dissolved in a chloroform:methanol mixture (9:1 v/v) and  DDA and TDB 146 
mixed to a final concentration of 1.25 mg and 0.25 mg DDA and TDB per mL respectively, representing 147 
a 5:1 DDA/TDB weight ratio (8:1 molar ratio). To investigate the incorporation of resiquimod onto the 148 
liposomes formulations, DDA:TDB liposomes were formulated with inclusion of the DSPE-resiquimod 149 
conjugate to a final concentration of  0.185 mg per mL. To serve as a control, resiquimod was added 150 
to pre-formed DDA:TDB:DSPE liposomes at the same molar ratio. Therefore each dose contained 0.4 151 
μmol lipid (DDA), 0.05 μmol TDB, 0.032 μmol DSPE lipid and 0.032 μmol resiquimod. Lipid mixtures 152 
were added to a round bottomed flask and upon solvent extraction via rotary evaporation and N2 153 
flushing, a dry film was produced. The lipid film was hydrated in Tris-buffer (10 mM, pH 7.4) for 20 154 
min at 10 °C above the main gel-to-liquid phase transition (DDA at ~47 °C). The subunit protein antigen, 155 
H56 (Ag85B-ESAT6-Rv2660c) was added at an in vivo dose of 5 μg (0.1 mg/mL formulation). 156 
 157 
Characterisation of particle size and zeta potential for liposome-delivery systems 158 
The intensity mean diameter of all liposome formulations were measured using a Malvern Zetasizer 159 
Nano-ZS (Malvern Instruments, Worcs., UK) via dynamic light scattering (DLS). Vesicle size and zeta 160 
potential were measured in triplicate at 25 ˚C by diluting liposomes 1 in 10 in Tris buffer (1 mM, pH 161 
7.4).  162 
 163 
Radiolabelling of Antigen 164 
The protein antigen, H56 (Ag85B-ESAT6-Rv2660c), was radiolabelled with 125I using pre-coated 165 
iodination tubes [(or IODOGEN® tubes) Pierce Biotechnology, Rockford, IL). Separation of 125I 166 
radiolabelled protein from free 125I was carried out using a Sephadex G-75 gel column, pre-soaked in 167 
ddH2O and equilibrated with Tris buffer. This method was carried out as described previously [5]. 168 
 169 
Radiolabelling of TLR agonist 170 
During this investigation it was required to determine the agonist loading and also to track the 171 
biodistribution of TLR agonist in vivo. Resiquimod or DSPE-conjugated resiquimod was radiolabelled 172 
with 125I in an IODO-GEN® tube and left for 1 hour with intermittent swirling. Following the radiolabel, 173 
these two products can be incorporated within liposome formulations as described. Due to the 174 
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radiolabelling procedure not being 100 % efficient there may still be some free 125I. This was removed 175 
by using sodium thiosulphate (Na2SO3), which will convert free iodine to iodide (I2  2I-), followed by 176 
extended dialysis (using 3 kDa dialysis tubing).  177 
 178 
Antigen and agonist loading in simulated in vivo conditions 179 
Radiolabelled H56 or resiquimod (antigen and TLR agonist respectively) were added to each liposome 180 
formulation at an in vivo concentration of 5 μg and 10 μg per dose (0.1 or 0.2 mg/mL) respectively, 181 
and left to adsorb to the liposome for 45 minutes with intermittent swirling. Surface-associated and 182 
unadsorbed antigen/agonist was separated from liposomes by diluting the suspension to 1 mL using 183 
Tris buffer, followed by centrifugation on an Optima Max-XP Ultracentrifuge (Beckman-Coulter Inc., 184 
Fullerton, CA) at a speed of 125,000 x g (45 minutes at 4 °C). The quantity of radiolabelled antigen or 185 
TLR agonist (125I-H56, and 125I-Resiquimod or 125I-Resiquimod-DSPE) prior to centrifugation, and within 186 
subsequent fractions (pellet and supernatant) was measured using a Cobra™ CPM Auto-Gamma® 187 
counter (Packard Instruments Company Inc., Downers Grove, IL). The total recovery and adsorption 188 
of protein antigen or TLR agonist was then determined by calculating the % radioactivity in the 189 
liposome pellet fraction. Antigen and Agonist retention studies were undertaken in simulated in vivo 190 
conditions (50% FCS in Tris buffer, 37 °C) with samples processed as above at periodic intervals. 191 
 192 
Biodistribution studies to investigation the localisation of vaccine components upon intramuscular 193 
injection 194 
Experimentation strictly adhered to the 1986 Scientific Procedures Act (UK). All protocols have been 195 
subject to ethical review and were carried out in a designated establishment. Groups of four 6–8 week 196 
old female BALB/c mice were housed appropriately and given a standard mouse diet ad-libitum. Four 197 
to six days prior to each vaccination, mice were injected subcutaneously (s.c.) with 200 μl pontamine 198 
blue (Sigma Aldrich, 0.5% w/v in PBS). Pontamine blue is phagocytosed by monocytes [38] and is 199 
therefore a suitable marker for aiding location of lymph nodes during dissection. Liposomes composed 200 
of DDA in combination with TDB, with either DSPE-Resiquimod conjugate (DDA:TDB-Res) or DSPE with 201 
post-LH addition of resiquimod (DDA:TDB:Res) and the tracer lipid 3H-cholesterol were produced with 202 
the addition of trehalose (10% w/v) to the hydrating Tris buffer in order to maintain isotonicity. 125I-203 
labelled Resiquimod or DSPE-Resiquimod were incorporated with the liposomes as appropriate. 204 
Subsequently, unlabelled H56 antigen was added to the various liposome formulations at an in vivo 205 
dose of 5 µg (0.1 mg/mL). Each immunisation dose contained 0.4 μmol lipid (DDA), 0.05 μmol TDB, 206 
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0.032 μmol DSPE lipid and 0.032 μmol resiquimod and 5 μg H56. Mice were injected im (50 μL) into 207 
the left quadricep. Each immunisation dose contained 100 kBq 125I (radiolabelled agonist) and 100 kBq 208 
3H-Chol (radiolabelled liposomes). At time points 1, 4 and 8 days post injection (pi), mice were 209 
terminated by cervical dislocation. Tissue from the injected muscle site (SOI), local draining popliteal 210 
lymph node (PLN) were removed and processed as described previously [39, 40] to determine the 211 
proportion of 3H (liposome) and 125I (agonist) in the tissues. 212 
 213 
Immunisation studies 214 
All experiments were undertaken in accordance with the Scientific Procedures Act of 1986 (UK). 215 
Female C57BL/6 mice, 6-8 weeks old (Charles River, UK) were split into 5 groups of 5 mice. Vaccine 216 
formulations were prepared by the lipid film-hydration method with the liposomes adsorbing H56 217 
antigen at a final concentration of 0.1 mg/mL (5 µg dose). These formulations were prepared with the 218 
addition of trehalose (10 % w/v) to the hydration buffer in order to maintain isotonicity. All mice were 219 
immunised intramuscularly into the left quadricep (50 µL/dose) three times (days 0, 14 and 28) and at 220 
scheduled time points, blood samples were taken from the tail and stored at -20 °C for future analysis 221 
of antibodies. 222 
 223 
Evaluation of H56-antigen specific antibody isotypes 224 
Samples of blood sera were collected on day 46 for the detection of IgG, IgG1 and IgG2b antibodies 225 
(AbD Serotec, Oxford, UK). Blood (50 μL) was collected via tail-bleeding using capillary tubes coated 226 
with 1% (w/v) heparin (Sigma Aldrich). Blood was diluted 10-fold in PBS and centrifuged at 10,000 x g 227 
(room temperature for 5 minutes) to obtain blood sera and frozen at – 20 °C for future analysis. 228 
Standard ELISA protocol was used to detect antibodies against H56. Plates were coated with H56 229 
antigen (5 μg/mL in PBS) before overnight incubation at 4 °C. The following day, plates were washed 230 
and blocked with skimmed milk powder (4 % w/v in PBS) for 1 hour. Serially diluted (100 µL) serum 231 
was added to washed plates and incubated at 37 °C for 1 hour. In order to detect anti-H56 antibodies, 232 
goat anti-mouse IgG (1:750) and IgG1(1:4000) were added to wells and incubated for 1 hour at 37 °C 233 
followed by washing and addition of 2,2′-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) [ABTS] 234 
substrate solution in citrate buffer incorporating 5 μl of 30% H2O2/50 ml citrate buffer. Absorbance 235 
was read at 405 nm (BioRad, Herts., UK) and the results expressed as the mean of 5 mice per group ± 236 
SD of the log10 of the reciprocal end-point dilution. 237 
 238 
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Cytokine analysis from restimulated splenocytes and popliteal lymph nodes 239 
At the final time point (day 49) of the vaccine study, mice were terminated and spleens were collected. 240 
Spleen cell suspensions were produced by mashing through a fine wire mesh into 10 mL RPMI 1640 241 
cell culture medium supplemented with 10% FBS and 1% PSG. Cell suspensions were washed twice 242 
with complete RPMI (cRPMI) and resuspended to a final concentration of 8 x 106 cell/mL. Cells were 243 
plated in 96-well cell culture plates (100 µL/well) restimulated with either cRPMI alone (negative 244 
control), H56 antigen diluted in cRPMI to final concentrations of 0.05, 0.5 or 5 µg/mL, or with 245 
concanavalin A (positive control) to a final concentration of 2 µg/mL. 246 
Following 72 h incubation at 37 °C, supernatants were removed and pooled according to group and 247 
restimulation condition. Duoset® Capture ELISA kits were used according to the manufacturer’s 248 
instructions to detect IL-2, IL-5, IL-6, IL-10 and IFN-γ (R&D, Abingdon, UK) in the supernatants. During 249 
this protocol, ELISA plates were coated overnight with capture antibody (at room temperature). The 250 
following day, plates were washed followed by blocking with 1 % BSA (in PBS). Samples and serially 251 
diluted standards were added to washed plates and incubated for 2 hours at room temperature. 252 
Cytokines were detected by addition of detection antibody, streptavidin-HRP conjugate (1:200 253 
dilution), TMB substrate solution and stop solution (2N H2SO4). The OD at 450 nm was measured 254 
(BioRad, Herts., UK) and a sigmoidal standard curve for each cytokine standard was created to 255 
determine cytokine concentrations in these supernatant samples obtained from restimulated 256 
splenocytes. 257 
 258 
Statistical analysis 259 
Data was tested by one-way analysis of variance (ANOVA) followed by the post-hoc Tukey test in order 260 
to compare the mean values of different groups. Differences were considered to be statistically 261 
significant at p < 0.05 in all studies. All experiments were carried out in triplicate. 262 
Results  263 
Preparation of the lipid-Resiquimod conjugate 264 
Various chemical approaches conjugating a lipid with a TLR agonist were investigated. Resiquimod, 265 
besides its well-known immunogenicity, also has a chemical structure that enables lipid conjugation. 266 
DSPE contains a nucleophilic amine and resiquimod contains a tertiary alcohol, making the anhydride 267 
of succinic acid an ideal linker agent. Experimentally, succinic anhydride SA was found the best linker 268 
molecule. SA formed in quantitative yield the stage 1 succinamide intermediate containing a free 269 
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carboxylic acid for subsequent reaction (Figure 1).  Generally, agents to activate the carboxylic acid 270 
are used for esterification, but here a tertiary alcohol had to be coupled and this was performed best 271 
with the Mitsunobu Reaction. The Mitsunobu reaction is a unique dehydration-condensation reaction 272 
between alcohols and various other nucleophiles [41-43]. The tertiary alcohol of resiquimod is 273 
essential for TLR7/8 agonist properties and chemically this is providing a reactive substrate for SN1 274 
nucleophilic substitutions reactions.  Under Mitsunobu conditions with DIAD as activating agent, the 275 
carboxylic acid acted as nucleophile and was coupled in presence of triphenyl phosphine into the 276 
conjugated DSPE – resiquimod.  Thus, the chemically lipid bound TLR agonist resiquimod was obtained 277 
in only 2 chemical steps in high yields as a solid material and only one chromatographic purification 278 
was required. The covalently bound TLR agonist resiquimod, which is an approved pharmaceutical 279 
ingredient, is a key feature in this approach. In the experimental section the fully optimised reaction 280 
is reported and the ease of monitoring the reaction by TLC was found ideal in a pharmaceutical 281 
laboratory setting. Products and by-products of the reaction, such as triphenyl phosphine oxide [41, 282 
44]  indicate the progress of the reaction and the stage 1 intermediate can be in situ converted into 283 
the fully conjugated final product, which was then purified by column chromatography to give an 284 
analytical pure material.  285 
 286 
 287 
 288 
 289 
 290 
 291 
 292 
 293 
 294 
 295 
 296 
 297 
Figure 1. Conjugation of DSPE to Resiquimod. Step 1 includes the linker formation with SA and in step 2 the 298 
succinylated 1,2-distearoyl-sn-glycero-phosphoethanolamine (DSPE) is conjugated to resiquimod in a Mitsunobu 299 
reaction. 300 
Step 1:  
Succinylation Reaction 
Step 2:  
Mitsunobu Esterification 
Reaction 
Product: 
11 
 
Formulation of cationic liposomes displaying a lipidated TLR7/8 agonist  301 
As mentioned, DDA:TDB liposomes have been shown to be effective adjuvants in a range of studies 302 
[1, 4, 11, 45-49] and the aim of this work was to further potentiate the efficacy of these liposomes 303 
through the presence of resiquimod on the liposome surface. Therefore, to consider the impact of the 304 
addition of the lipid-TLR agonist conjugate on the formulation, a range of physico-chemical studies 305 
were conducted to compare DDA:TDB liposomes to liposomes prepared from DDA:TDB:DSPE mixed 306 
with resiquimod (DDA:TDB:Res) and liposomes prepared with the DSPE-resiquimod conjugate 307 
(DDA:TDB-Res). All formulations were prepared alone or with the addition of H56 antigen (Figure 2).  308 
Liposomes without the addition of H56 antigen were in the range of 400 to 600 nm, with PDI values 309 
around 0.2 to 0.5 irrespective of the presence of resiquimod (Figure 2A). The addition of H56, which 310 
electrostatically binds to the cationic liposomes, results in a general trend of increased vesicle size and 311 
PDI across all three formulations (Figure 2A). With regard to the cationic nature of the liposomes, this 312 
remains similar and high for all three liposome formulations, with and without the presence of the 313 
H56 antigen (approximately 60-70 mV; Figure 2B).  314 
 315 
 316 
 317 
 318 
 319 
 320 
 321 
 322 
 323 
 324 
 325 
 326 
 327 
Figure 2. Characterisation of liposome 
product. The vesicle size and PDI (A) and 
zeta potential (B) of the DDA:TDB 
liposomes with and without the addition 
of H56 antigen (DDA:TDB and 
DDA:TDB:H56), and either mixed with 
resiquimod (DDA:TDB:Res) or with 
resiquimod conjugated to the liposome 
(DDA:TDB-Res). All results represent mean 
± SD of 3 independent liposome batches. 
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The cationic nature of these liposomes promotes high antigen loading at the doses used, with 328 
approximately 85% antigen loading for all three liposome formulations (Figure 3A). To consider the 329 
association of resiquimod with the liposome formulations, the loading of resiquimod was also 330 
measured. Simple mixing of resiquimod with cationic liposomes (DDA:TDB:Res) resulted in low agonist 331 
association (approximately 15%; Figure 3A), as would be expected given there is little ability of 332 
electrostatic interactions between the cationic liposomes and resiquimod. In contrast, over 85% 333 
resiquimod was incorporated within the liposome formulation using the lipid-resiquimod conjugate 334 
(DDA:TDB-Res; Figure 3A).  Antigen and agonist retention to these various liposomes was also tested 335 
in a simulated in vivo environment (50 % FCS in Tris buffer (10 mM); 37 °C). Following a burst release 336 
over the initial 3 hours of the study (10-20%), antigen release stabilised over the rest of the 96-hour 337 
period (Figure 3B). This demonstrates that antigen can be retained by the delivery system even under 338 
simulated in vivo conditions with the presence of conjugated resiquimod making no significant 339 
difference. In terms of TLR7/8 agonist retention, high levels of resiquimod conjugate was retained by 340 
the DDA:TDB liposomes (DDA:TDB-Res; Figure 3C). This confirms that both antigen and lipidated 341 
resiquimod can be efficiently retained by cationic liposomal adjuvants in simulated in vivo conditions. 342 
This may be important as recent studies have suggested that the co-localisation of antigen and 343 
immunostimulators is important for optimal vaccine adjuvant activity [8] as simultaneous delivery of 344 
these to the same antigen presenting cell is crucial for the downstream vaccine-mediated immune 345 
responses.  346 
 347 
 348 
 349 
 350 
 351 
 352 
 353 
 354 
 355 
 356 
 357 
Figure 3. Antigen and Agonist 
loading and retention on liposomes; 
A) shows the Antigen (H56) and 
Agonist (resiquimod) loading on the 
three liposome formulations; B) 
shows the antigen retention with 
the three liposome formulations 
over 98 h; C) shows resiquimod 
retention when conjugated to the 
liposomes. All results represent 
mean ± SD of 3 independent 
liposome batches. 
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Conjugation of a TLR7/8 agonist to cationic liposomes avoids rapid distribution and promotes a 358 
depot of both liposomes and TLR agonist at the injection site. 359 
Previous studies have suggested that the ability to form a depot is important for the function of many 360 
adjuvants [5, 6, 51] and through a range of studies, we have demonstrated the depot forming effect 361 
of DDA:TDB liposomes [5, 6, 39]. Based on this, we compared the biodistribution of the three liposome 362 
formulations to consider the ability of the liposome formulation containing conjugated resiquimod 363 
(DDA:TDB-Res) to retain the TLR agonist with the liposomes (Figure 4).  364 
Incorporation of DSPE (either lipid alone or the lipid-TLR7/8 conjugate, both present at the same molar 365 
ratio) had no significant effect on liposome retention at the injection site all time points measured, 366 
with all formulations studied showing a liposome depot effect (Figure 4A). At day 1 pi, DDA:TDB gave 367 
liposome dose retention of ~ 85 % (in-line with previous studies [5, 51]) with approximately 30 % of 368 
the dose remaining at day 8. With the addition of DSPE in the bilayer and free resiquimod in the 369 
formulation (DDA:TDB:Res), or the liposome formulation with conjugated resiquimod (DDA:TDB-Res,) 370 
similar levels of liposomes remained at the injection site (70-75 % remaining at day 1, 40 % after 4 371 
days, and 25 % of the dose remaining at 8 day pi; figure 4A). This is in line with the data presented in 372 
Figures 2 and 3, which demonstrates that the presence of the additional lipid (DSPE) with or without 373 
resiquimod conjugated made no impact on the measured physico-chemical attributes nor the 374 
biodistribution of the vesicles.  375 
When considering resiquimod retention at the depot site, high levels (70 %, 40 % and 24 % of the dose 376 
at days 1, 4 and 8 pi respectively; Figure 4B) were retained at the depot site along with the liposomes, 377 
when resiquimod was conjugated to the liposomes. In contrast, after intramuscular injection of 378 
resiquimod either alone (Res) or mixed with DDA:TDB liposomes (DDA:TDB:Res) only low levels (6% 379 
or less) were detected after 24 h (Figure 4B), demonstrating the rapid clearance of resiquimod from 380 
the injection site when not conjugated to the liposomes. These results demonstrate the ability of the 381 
cationic liposomes with conjugated resiquimod to form a depot at the injection site.  382 
 383 
 384 
 385 
 386 
 387 
 388 
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 394 
 395 
 396 
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 398 
 399 
 400 
 401 
Figure 4. Biodistribution of liposomes and agonist. Liposome (A, C) and agonist dose retention (B, D) at the site 402 
of injection and draining lymph node respectively following i.m. injection of either DDA:TDB, DDA:TDB:Res or 403 
DDA:TDB-Res (all adsorbing H56 antigen) or resiquimod alone (negative control). The proportion of 3H or 125I 404 
radionucleotides at the injection site and draining lymph node as a percentage of the initial dose were calculated. 405 
Results represent the mean ± SD of four mice.  406 
 407 
When considering the movement to the draining lymph node (the popliteal lymph node; PLN), the 408 
cationic liposomes were shown to drain at a similar rate irrespective of the presence of free or 409 
conjugated resiquimod (Figure 4C). When tracking the presence of the agonist at the PLN, free 410 
resiquimod was shown to quickly drain to the lymph node and then rapidly clear (Figure 4D). In the 411 
case of resiquimod conjugated to DDA:TDB liposomes, the movement of resiquimod to the PLN maps 412 
closely to that of the liposomes, again demonstrating that the conjugation of resquimod to the cationic 413 
liposomes facilitates the movement of the antigen-adjuvant complex together from the site of 414 
injection to the local draining lymph node. 415 
Conjugation of a TLR7/8 agonist to cationic liposomes does not improve antibody responses. 416 
The ability of H56 vaccine antigen either delivered alone or in combination with the 3 different 417 
liposome formulations (DDA:TDB, DDA:TDB:Res, DDA:TDB-Res) to induce IgG (total), IgG1 and IgG2b 418 
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antibody isotypes was investigated using antibody ELISAs (Figure 5). Resiquimod alone was also used 419 
as a negative control. 420 
In general, all three liposome formulations induced similar immune responses for IgG, IgG1 and IgG2b 421 
these responses with no significant difference between the three formulations. All three formulations 422 
did promote significantly higher (P < 0.05) than responses generated in mice immunised with antigen 423 
alone. Also resiquimod alone-immunised mice (negative control) did not promote detectable antibody 424 
responses for all three antibody isotypes investigated (Figure 5).  425 
 426 
 427 
 428 
 429 
 430 
 431 
 432 
 433 
 434 
 435 
Co-delivery of Mincle and TLR7 agonist by liposomes does not influence Th1 cytokine production in 436 
restimulated cells from spleen and lymph nodes 437 
Both Mincle and TLR7 activation have been demonstrated to promote a vaccine-mediated skewing of 438 
the immune profile to a more Th1 directed response [16, 58]. Therefore, we investigated if dual 439 
activation of both receptors by the formulated DDA:TDB-Res liposomes would further boost Th1 440 
responses (Figure 6). Mice were vaccinated with H56 antigen in combination with DDA:TDB-Res, 441 
DDA:TDB mixed with Res (DDA:TDB:Res) or DDA:TDB liposomes and the supernatants of restimulated 442 
splenocytes and popliteal lymph nodes (PLN) were assayed for the presence of cytokines IFN-γ, IL17, 443 
IL-2, IL-6, IL-5 and IL-10. In line with previous reports highlighting the strong Th1-mediating effects of 444 
DDA:TDB liposomes [4, 47, 48], high levels of IFN-γ and low levels of IL-5 and IL-10 were noted with 445 
cells from both the spleen and local lymph node (Figure 6A and B respectively).  The results in figure 446 
6 show that all three liposome formulations enhanced cellular immunity but the benefit of including 447 
Figure 5. H56-antigen specific 
antibody responses in the 
blood sera (IgG, IgG1, IgG2b). 
Blood was collected at day 46 
from mice immunised with 
H56 in combination with 
either DDA:TDB, 
DDA:TDB:Res or DDA:TDB-
Res. As negative controls, 
resiquimod and H56 antigen 
were injected alone. Mice 
received 3 injections with 2-
week intervals. Results 
represent the mean of 5 mice 
per experimental group ± SD. 
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the resquimod is not clear. Across the cytokines tested, whilst there are some improvements in IFN-ƴ 448 
production this is already high for the cationic liposomes. This data, combined with the antibody data, 449 
suggests that whilst conjugation of resiquimod to the liposomes successfully co-delivers the liposomes 450 
with the resiquimod and the antigen, there is no notable improvement in immune response profiles.  451 
 452 
 453 
 454 
 455 
 456 
 457 
 458 
 459 
 460 
Figure 6. Cytokine production (IFN-γ, IL-17, IL-2, IL-5, IL-6 and IL-10) from cultured restimulated spleen 461 
(A) and popliteal lymph node (B) cells derived from mice immunised with H56 in combination with 462 
either DDA:TDB, DDA:TDB:Res, DDA:TDB-Res. As negative controls, resiquimod and H56 antigen were 463 
injected alone. Mice received 3 injections with 2-week intervals and cells were obtained 3 weeks post 464 
the final immunisation. Cells were restimulated for 72 hrs in the presence of H56 (at 5 μg/mL). 465 
Cytokines were detected from spleen (A) and popliteal lymph node (B) cell supernatants and 466 
measured using sandwich ELISAs. Results represent the mean of 5 mice per group ± SD. 467 
Discussion 468 
In this study we have demonstrated that the TLR7 agonist resiquimod can be redesigned to include a 469 
DSPE lipid tail, which allows for insertion into cationic liposomes stabilised by TDB. The lipidated 470 
resiquimod was stable and remains bound to the DDA:TDB liposomes. In contrast, simple mixing of 471 
resiquimod with cationic liposomes resulted in low agonist loading, as expected given there is little 472 
ability of electrostatic interactions between the cationic liposomes and resiquimod in its native state. 473 
Thus it is reasonable to expect that incorporation of lipidated resiquimod to the DDA:TDB liposomes 474 
allowed for co-delivery of Mincle and TLR7 agonists to the same antigen presenting cell. 475 
Many studies have demonstrated the ability of TLR7 agonists to boost vaccine-induced immune 476 
responses [58,59].  Further boosting or redirection of immune responses by co-adjuvantation of TLR7 477 
agonists with other adjuvants has also been described. E.g. alum precipitated TLR7 agonists (alum-478 
TLR7) were shown to boost antibody titers to a glycoconjugate vaccine (CRM197-MenC), an acellular 479 
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pertussis vaccine and a protein-based vaccine against Staphylococcus aureus in mice. Furthermore, 480 
this inclusion of a TLR7 agonist with Alum re-directed the alum-induced Th2 flavoured response 481 
towards a more Th1-biased immune profile [60-62]. Using anionic liposomes, Fox et al. demonstrated 482 
that co-delivery of the TLR4 agonist GLA and the TLR7 agonist imiquimod increased Th1 responses 483 
[27]. Cationic liposomes containing TDB (CAF01) already induce a strong Th1 profile associated with 484 
high levels of CD4+ T cells producing IFN-ɣ [58]. Interestingly, we found that formulating the TLR7 485 
agonist resiquimod into the liposomes made no notable  impact on the IFN-ɣ, IL-2 and TNF-α responses 486 
upon reactivation of splenocytes. Therefore, there is no clear evidence to support a distinctive 487 
increase in immune responses and why the more complex resiquimod conjugated formulation should 488 
be adopted over the simple cationic liposome formulation.  However, it is possible that there could be 489 
a greater benefit seen in humans or larger animals.  490 
Resiquimod as a TLR7 and 8 agonist has been reported to induce Th1 cytokine responses through a 491 
variety of mechanisms. It activates the DCs by binding the TLR7 which are largely located in the 492 
endosomal compartments on DCs giving rise to the production of type I IFN [54, 55], upregulation of 493 
MHCII and the co-stimulatory receptors CD80 and CD86 [63]. TLR8 is mainly expressed on 494 
macrophages and monocytes which generate TNF-α and IL-12 cytokines and thus, contribute to the 495 
increased Th1 response [53, 54]. However, despite resiquimods dual ligation of both TLRs, in mice it 496 
only exerts its effect by binding to TLR7 as TLR8 is non-functional in mice [56]. 497 
As we have demonstrated here, lipidation of the TLR7 agonist resiquimod was necessary for the 498 
compound to stably associate with cationic liposomes. However, the lipidation may also in itself have 499 
an effect on activation of the immune response. Other lipidated TLR7/8 agonists have been described, 500 
e.g. the imidazoquinoline 3M-052 bearing a fatty acyl C18 lipid moiety [16]. Notably, it was found that 501 
this compound formulated in dioleoylphosphatidylcholine liposomes resulted in a boost of local 502 
immunity at the site of injection and in draining lymph nodes rather than more systemic effects, which 503 
may have the advantage that it minimizes the cytokine storm-like effects that is one concern for the 504 
small-molecule TLR7/8 agonists [16, 32].  505 
An important consideration for experimental vaccines is translation of the immune profile from small 506 
animal species to humans. Whilst no vaccines including TLR7/8 ligands are yet licensed,  studies in 507 
monkeys have shown that including a TLR7/8 agonist allows for boosting of anti-HIV Envelope IgG 508 
responses compared to when alum was used alone [64, 65]. Furthermore, the capability of co-509 
adjuvantation with TLR7 agonists to redirect the alum-induced T cell responses towards IFN-ɣ 510 
producing Th1 cells was also demonstrated in monkeys [67]. It was recently found that a TLR7/8 511 
agonist can boost antibody titers to pneumococcal conjugate vaccine at birth [66]. Immunity is 512 
18 
 
impaired at the extremes of age. Particularly, neonates and elderly have poor responses to several 513 
TLR agonists and vaccine responses are therefore impaired in these populations. Dual targeting of 514 
pathogen recognition receptors is one promising strategy to boost the low vaccine-induced immune 515 
responses observed in neonates and elderly [66, 67]. The potential to overcome the impaired 516 
immunity of specific age or immunocompromised risk groups is therefore also an important 517 
application for future studies of the adjuvant combination developed in the present study.    518 
Conclusions 519 
During these studies we have been able to design and synthesise a novel conjugate between lipid and 520 
TLR7/8 agonist, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine and resiquimod respectively. This 521 
novel lipid-resiquimod conjugate can be effectively incorporated into cationic liposomes. These 522 
liposomes form a depot at the injection site allowing the liposomes, antigen and TLR7/8 agonist to be 523 
co-located and co-presented. However, this did not notable enhance antibody nor cytokine responses, 524 
with strong Th1 cytokine responses seen with the cationic liposomes irrespective of the presence of 525 
the conjugated resiquimod. This suggests that despite co-delivery, the presence of the TLR7/8 on the 526 
cationic liposome formulation was not able to further potentiate the strong responses generated by 527 
this cationic adjuvant. 528 
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Figure legends 745 
Figure 1. Conjugation of DSPE to Resiquimod. Step 1 includes the linker formation with SA and in step 746 
2 the succinylated 1,2-distearoyl-sn-glycero-phosphoethanolamine (DSPE) is conjugated to 747 
resiquimod in a Mitsunobu reaction. 748 
Figure 2. Characterisation of liposome product. The vesicle size and PDI (A) and zeta potential (B) of 749 
the DDA:TDB liposomes with and without the addition of H56 antigen (DDA:TDB and DDA:TDB:H56), 750 
and either mixed with resiquimod (DDA:TDB:Res) or with resiquimod conjugated to the liposome 751 
(DDA:TDB-Res). All results represent mean ± SD of 3 independent liposome batches. 752 
Figure 3. Antigen and Agonist loading and retention on liposomes; A) shows the Antigen (H56) and 753 
Agonist (resiquimod) loading on the three liposome formulations; B) shows the antigen retention with 754 
the three liposome formulations over 98 h; C) shows resiquimod retention when conjugated to the 755 
liposomes. All results represent mean ± SD of 3 independent liposome batches. 756 
Figure 4. Biodistribution of liposomes and agonist. Liposome (A, C) and agonist dose retention (B, D) 757 
at the site of injection and draining lymph node respectively following i.m. injection of either DDA:TDB, 758 
DDA:TDB:Res or DDA:TDB-Res (all adsorbing H56 antigen) or resiquimod alone (negative control). The 759 
proportion of 3H or 125I radionucleotides at the injection site and draining lymph node as a percentage 760 
of the initial dose were calculated. Results represent the mean ± SD of four mice.  761 
Figure 5. H56-antigen specific antibody responses in the blood sera (IgG, IgG1, IgG2b). Blood was 762 
collected at day 46 from mice immunised with H56 in combination with either DDA:TDB, DDA:TDB:Res 763 
or DDA:TDB-Res. As negative controls, resiquimod and H56 antigen were injected alone. Mice received 764 
3 injections with 2-week intervals. Results represent the mean of 5 mice per experimental group ± SD. 765 
Figure 6. Cytokine production (IFN-γ, IL-17, IL-2, IL-5, IL-6 and IL-10) from cultured restimulated spleen 766 
(A) and popliteal lymph node (B) cells derived from mice immunised with H56 in combination with 767 
either DDA:TDB, DDA:TDB:Res, DDA:TDB-Res. As negative controls, resiquimod and H56 antigen were 768 
injected alone. Mice received 3 injections with 2-week intervals and cells were obtained 3 weeks post 769 
the final immunisation. Cells were restimulated for 72 hrs in the presence of H56 (at 5 μg/mL). 770 
Cytokines were detected from spleen (A) and popliteal lymph node (B) cell supernatants and 771 
measured using sandwich ELISAs. Results represent the mean of 5 mice per group ± SD. 772 
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